The ABC of Alzheimer's Disease: ADL and Improving Day-to-Day Functioning of Patients
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by deterioration in the ability to perform activities of daily living (ADL) in addition to loss of cognitive function and behavioral changes. This decline in day-to-day functioning is increasingly recognized as a source of considerable social, health, and economic costs. Inability to perform ADL results in growing caregiver burden and may lead to the eventual need for alternative care or nursing home placement. The measurement of ADL, which enables monitoring of the effectiveness of therapeutic interventions, can be performed using a number of inventories including the Progressive Deterioration Scale (PDS), the Disability Assessment for Dementia (DAD), and the Alzheimer Disease Cooperative Study ADL (ADCS/ADL) assessment scale. Clinical studies using these and other scales have indicated that cholinesterase (ChE) inhibitors offer an effective approach to treating the functional decline of AD. Donepezil, rivastigmine, and galantamine have been shown in some studies to prevent or slow decline in ADL over treatment periods of one to two years. For instance, in a 24-week study in subjects with moderate to severe AD, donepezil-treated patients remained stable compared with the placebo-treated patients. Rivastigmine has shown improvement or stabilization of PDS scores in patients with mild to moderate disease following 26 weeks of treatment and slowed deterioration in patients with more severe disease. Evidence to date suggests that these agents may not be equally effective at slowing or stabilizing loss in ADL over time and that these differences may reflect differences in pharmacology. In addition to inhibition of acetylcholinesterase (AChE), these compounds have other putative differences in mechanisms of action. Galantamine allosterically modulates the nicotinic receptor and may prevent the loss of ADL. Rivastigmine robustly inhibits butyrylcholinesterase in addition to AChE and therefore acts as a dual ChE inhibitor. Comparative studies evaluating the differential effects of these ChE inhibitors on ADL are awaited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schulz, R., O'Brien, A. T., Bookwala, J., & Fleissner, K. (1995) · The Gerontologist · doi:10.1093/geront/35.6.771 · Cited by 1,765
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Accelerated risk of hypertensive blood pressure recordings among alzheimer caregivers
Shaw, W. S., Patterson, T. L., Ziegler, M. G., Dimsdale, J. E., Semple, S. J., & Grant, I. (1999) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(98)00084-1 · Cited by 211
Cited by
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
Andersen, C. K., Wittrup-Jensen, K. U., Lolk, A., Andersen, K., & Kragh-Sørensen, P. (2004) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-2-52 · Cited by 365
Carpenter, G. I., Hastie, C. L., Morris, J. N., Fries, B. E., & Ankri, J. (2006) · BMC Geriatrics · doi:10.1186/1471-2318-6-7 · Cited by 212
“The relationship between cognition and ADL has become an increasingly important area of dementia research as it can help to inform treatment decisions and it can help in the understanding of the value of new generations of pharmaceutical agents which aim to enhance cognitive function [14].”
BackgroundPless, A., Ware, D., Saggu, S., Rehman, H., Morgan, J., & Wang, Q. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1263771 · Cited by 131
Vitlic, A., Lord, J. M., & Phillips, A. C. (2014) · AGE · doi:10.1007/s11357-014-9631-6 · Cited by 123
Metadata
- Authors
- Potkin, S. G.
- Venue
- International Psychogeriatrics
- Publisher
- Elsevier BV
- Published
- 2002-02
- Volume
- 14
- Pages
- 7-26
- ISSN
- 1041-6102 (ISSN-L)
- OpenAlex
- W2084185169
- Cited by
- 80
- References
- 5
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The ABC of Alzheimer's Disease: ADL and Improving Day-to-Day Functioning of Patients. https://app.cochat.ai/papers/10.1017/s1041610203008640
- The paper
- Potkin, S. G. (2002). The ABC of Alzheimer's Disease: ADL and Improving Day-to-Day Functioning of Patients. International Psychogeriatrics. https://doi.org/10.1017/s1041610203008640
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.